Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Export ban and fines loom as Greek liquidity crisis reaches saturation point and first company pulls out

This article was originally published in Scrip

Executive Summary

With the news that the first drug company has buckled under pressure and decided to withdraw from the Greek market comes concern that other suppliers may follow suit. Meanwhile, existing drug shortages caused by the liquidity crisis are being exacerbated by parallel exports, according to Greek state medicines organisation EOF, which has threatened to ban such activity for certain medicines and fine companies if the problem persists.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC017859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel